4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
CAMBRIDGE, UK – June 15, 2026 – 4basebio PLC (AIM: 4BB), a specialist in specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, today announces the appointment of Jeff Coller, Ph.D., to its Strategic Advisory Board (SAB). A globally recognised figure in mRNA biology and translation, Dr. Coller’s expertise will assist with the Company’s efforts to reshape the scalable manufacturing of next-generation nucleic acid therapeutics.
CAMBRIDGE, UK – June 15, 2026 – 4basebio PLC (AIM: 4BB), a specialist in specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, today announces the appointment of Jeff Coller, Ph.D., to its Strategic Advisory Board (SAB). A globally recognised figure in mRNA biology and translation, Dr. Coller’s expertise will assist with the Company’s efforts to reshape the scalable manufacturing of next-generation nucleic acid therapeutics.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.